New Delhi: The Indian government has initiated a probe into manufacturing of four cough syrups by a Haryana-based pharmaceutical firm after an alert was issued by the World Health Organization (WHO).
The news agency PTI quoted a source saying, “While all required steps will be taken, as a robust regulatory authority, WHO has been requested to share with CDSCO (Central Drugs Standard Control Organisation) the earliest the report on the establishment of a causal relation to the deaths with the medical products in question, photographs of labels/products etc.”
Also Read: Jaishankar urged fast visa for students in talks with New Zealand counterpart
The WHO stated that the syrups could be linked to death of 66 children in the Gambia. It added that the manufacturer has not provided guarantees to WHO on the safety and quality of these products.
“Laboratory analysis of samples of each of the four products confirms that they contain unacceptable amounts of diethylene glycol and ethylene glycol as contaminants. To date, these four products have been identified in The Gambia, but may have been distributed, through informal markets, to other countries or regions,” said the WHO.
Also Read: PM expresses anguish over mishap during idol immersion in WB’s Jalpaiguri
The four products are Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup.
